First-Line Treatment of mNSCLC with Combination Immunotherapy plus Chemotherapy and Key Data Updates from POSEIDON
In the second installment of this series, Edward B. Garon, MD, MS, explains the rationale for using combination IO therapies alongside chemotherapy for first-line treatment of metastatic non-small cell lung cancer (NSCLC), discusses key data from the POSEIDON trial presented at recent meetings, and elaborates on how these regimens may change his clinical practice.
EP: 1.Overview of Immune Checkpoint Inhibitors in NSCLC
EP: 2.A Historical Perspective on First-Line Treatment of NSCLC and Recent Advances in Immunotherapy
EP: 3.First-Line Treatment Paradigm of NSCLC and the Advent of Immunotherapy
EP: 4.First-Line Treatment of mNSCLC with Combination Immunotherapy plus Chemotherapy and Key Data Updates from POSEIDON
EP: 5.First-Line Combination Immunotherapy plus Chemotherapy in mNSCLC
EP: 6.Clinical Implications of Recent Advancements in Immunotherapy for NSCLC
EP: 7.Key Updates in the Changing NSCLC Treatment Landscape
Nogapendekin Alfa Plus Checkpoint Inhibition Improves Survival in NSCLC
April 25th 2024Following its recent FDA approval in non-muscle-invasive bladder cancer, nogapendekin alfa has also shown overall survival benefits in addition to checkpoint inhibitor therapy in patients with non-small cell lung cancer.
Read More
Emphasizing the Need for NGS in Advanced NSCLC to Determine Treatment
April 23rd 2024During a Case-Based Roundtable® event, Joshua Sabari, MD, led a discussion on the need for next-generation sequencing to determine treatment in patients with EGFR-positive advanced non–small cell lung cancer in the first article of a 2-part series.
Read More
